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INTRODUCTION
Prostate  cancer  is  the  most  common  noncutaneous  cancer 
among males.1 It accounts for 10% of cancer related deaths in males. 
According to the American Cancer Society, 186330 new cases will 
be diagnosed in 2008 and 26000 men will die from prostate cancer1. 
Prostate cancer is rarely diagnosed in men younger than 40 years, 
and it is uncommon in men younger than 50 years. Prostate cancer is 
also  found  during  autopsies  performed  following  other  causes  of 
death. The rate of this latent or autopsy cancer is much greater than 
that of clinical cancer. In fact, it may be as high as 80% by age 80 
years. 2
The diagnosis and treatment of  prostate cancer  continues to 
evolve.  With  the  development  of  prostate-specific  antigen  (PSA) 
screening and TRUS, prostate cancer is being diagnosed earlier in 
the disease course.
In  the  present  era,  most  patients  present  because  of 
abnormalities  in  Prostate  Specific  Antigen  (PSA)  level  or  positive 
digital  rectal  examination (DRE) findings while  evaluating for  BPH, 
rather  than  metastatic  symptoms.  The  combination  of  DRE  and 
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serum  PSA  is  the  most  useful  first-line  test  for  assessing  the 
presence  of  prostate  cancer  in  an  individual.3 However,  prostate 
cancer  can  be  an  incidental  pathologic  finding  when  tissue  is 
removed  during  transurethral  resection to  manage  obstructive 
prostatic symptoms.
The  presence  of  prostate  disease  (prostate  cancer,  BPH,  and 
prostatitis) is the most important factor affecting serum levels of PSA.4,5,6. 
PSA elevations may indicate the presence of prostate disease,  but not all 
men  with  prostate  disease  have  elevated  PSA levels.  Furthermore,  PSA 
elevations are not specific for cancer.
 Findings from the DRE are crucial. An irregular firm prostate or 
nodule is typical, but many cancers are found in prostates that feel 
normal. DRE is a test with only fair reproducibility even in the hands 
of  experienced  examiners that  misses  a  substantial  proportion  of 
cancers. 7,  8, 9 DRE detects most cancers at an advanced pathologic 
stage, when treatment is less likely to be effective. DRE misses 23% 
to  45% of  the  cancers  that  are  subsequently  found with  prostatic 
biopsies done for serum PSA elevations. 7
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A number of studies have confirmed the inability of TRUS to 
localise early prostate cancer. 10,  11,  12 Rifkin and colleagues10 found 
that  only 60% of prostate cancers measuring more than 5 mm on 
pathologic  examination  were  identified  by  MRI  and  that 
ultrasonography identified only 59% of these cancers. Flanigan and 
associates12 found that only 18% of 855 sonographically suspicious 
quadrants  actually  contained  cancer  on  biopsy,  whereas  65%  of 
quadrants  containing  cancer  were  not  sonographically  suspicious. 
Any patient  with a DRE suspicious for  cancer  or  a PSA elevation 
should undergo prostate biopsy regardless of  TRUS findings if  an 
early  diagnosis  of  cancer  would  result  in  a  recommendation  for 
treatment.
The original sextant biopsy scheme (one core from the base, 
mid,  and  apex  bilaterally)  significantly  improved  cancer  detection, 
over digitally directed biopsy of palpable nodules and TRUS guided 
biopsy of specific hypoechoic lesions. Presti  and co-workers found 
that  adding  laterally  directed  cores  from  the  base  and  midgland 
bilaterally improved cancer detection from 80% with standard sextant 
to 96%.13
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To improve the detection rate with TRUS biopsy various 
additional modalities have been tried. This includes power Doppler 
ultrasonography  to  evaluate  the  neovascularity  in  patients  with 
prostate  cancer.  Various  studies  have  shown  increased  cancer 
detection rates using  Doppler-targeted biopsy strategies.14,15,16,17 To 
evaluate  the  Indian  perspective  regarding  the  Doppler  directed 
targeted biopsy strategies, we decided to conduct a study to evaluate 
the  utility  of  power  Doppler  ultrasonography  in  the  detection  of 
prostate cancer.
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AIM
To evaluate the role of trans rectal ultrasound with power Doppler 
imaging guided biopsy in comparison with grey scale imaging in the 
detection of prostate cancer,  extended sextant biopsy being the 
reference standard.
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REVIEW OF LITERATURE
Prostate  cancer  is  the  fourth  most  common  male  malignant 
neoplasm worldwide.18 Prostate cancer has been the most common 
visceral malignant neoplasm in U.S. men since 1984, now accounting 
for one third of all  such cancers 1.  10% of cancer-related death in 
males is caused by prostate cancer1 The incidence of prostate cancer 
peaked in 1992, approximately 5 years after introduction of prostate-
specific antigen (PSA) as a screening test; it  fell  precipitously until 
1995 and has been rising slowly since then, at a slope similar to that 
observed before the PSA era. 19
According  to  figures  from  the  American  Cancer  Society, 
186,330 new cases will be diagnosed in 2008 and 26,000 men will 
die  from prostate  cancer.  Prostate  cancer  is  uncommon  in  men 
younger  than  50  years. 20 Prostate  cancer  is  also  found  during 
autopsies performed following other causes of death. The rate of this 
latent or autopsy cancer is much greater than that of clinical cancer. 
In fact, it may be as high as 80% by age 80 years. 1
The lifetime risk (from age 0 to 90 years) of death from prostate 
cancer is 3% and the lifetime risk of a diagnosis of prostate cancer is 
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17% 21
Anatomy and Internal Structure of the Prostate Gland
Overview of Prostate Anatomy 
The adult prostate is a chestnut-shaped organ enveloped in a 
fibrous capsule. The base of the prostate is attached to the bladder 
neck, and the apex is fixed to the urogenital diaphragm. The prostatic 
urethra traverses the gland. The verumontanum is a longitudinal ridge 
in  the  prostatic  apex  on  which  the  ejaculatory  ducts  open.  The 
prostate is related superiorly and posteriorly to the seminal vesicles. 
The ampullae of the vas deferens run medial to the seminal vesicles 
along  the  posterior  surface  of  the  prostate.  Anteriorly,  the  fibrous 
capsule thickens at the level of the apex to form the puboprostatic 
ligaments,  which attach the prostate to the back of  the symphysis 
pubis. The dorsal venous complex (i.e. Santorini’s plexus) runs along 
the  puboprostatic  ligaments.  The  prostate  gland  lies  beneath  the 
endopelvic  fascia.  Posteriorly,  the  2  layers  of  Denonvillier’s  fascia 
separate  the prostate from the rectum.  The rectourethralis  muscle 
attaches the rectum to the prostatic apex.
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A rich plexus of veins encompasses the prostate gland between 
the true fibrous capsule of the gland and the lateral prostatic fascia; 
these  are  visible  landmarks  on  sonograms.  The  neurovascular 
bundles run craniocaudally along the posterolateral  aspects of  the 
prostate. The prostate gland is supplied by the prostatic artery, which 
is usually a branch of the inferior vesical artery. The prostatic artery is 
divided into an urethral branch, which supplies the adenoma, and a 
capsular branch. Venous drainage from the prostate moves into the 
Santorini’s  plexus  and  eventually  into  the  internal  iliac  vein.  The 
prostatic  venous  plexus  communicates  freely  with  the  extradural 
venous plexus (i.e., Batson plexus), which is thought to be factor in 
the  spread  of  prostate  cancer.  Initially,  lymphatic  drainage  of  the 
prostate is into the obturator lymph nodes and into the hypogastric 
chain.
The nerve supply to the prostate is both sympathetic, from the 
hypogastric  plexus  (L1-2),  and  parasympathetic,  from  the  pelvic 
nerve (nervi erigentes (S2-S4). Although the cavernous nerves run 
along the posterior aspect of the prostate, the 2 distinct areas from 
which prostatic nerves leave the gland are thought to be the superior 
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and inferior pedicles. These areas are the first sites of extraprostatic 
spread of cancer.
Internal Architecture and Anatomy of the Prostate
According to the classic work by McNeal, the prostatic urethra, 
which is the main reference point of the prostate, divides the gland 
into an anterior fibromuscular stroma and a posterior glandular organ. 
The urethra angulates 35° anteriorly in the proximal portion of  the 
prostate. The ejaculatory ducts run in the same plane as the distal 
prostatic urethra to join the verumontanum. Lowsley's concept of a 5-
lobed  prostate  has  been  replaced  by  McNeal's  concept  of  zonal 
architecture. The prostate has 4 glandular zones, each with their own 
ductal system. The peripheral zone, transition zone, and periurethral 
glands have similar histological appearance and are derived from the 
urogenital sinus. However, the central zone is histologically distinct 
and is derived from mesonephric tissues (i.e., wolffian tissue).
Peripheral zone
The  peripheral  zone  constitutes  almost  75%  of  the  normal 
prostate gland. It occupies the distal prostate gland, the area around 
the urethra distal to the verumontanum. Their ducts drain distal to the 
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verumontanum.  Approximately  70%  of  carcinoma  of  the  prostate 
arise in this zone.
Central zone
The central zone constitutes 25% of the normal prostate and 
occupies  the  part  of  the  prostate  behind  the  proximal  prostatic 
urethra.  The  ejaculatory  ducts  traverse  through  the  central  zone. 
Approximately 5-10% of carcinoma of prostate arise in this zone.
Transition zone
The  transition  zone  makes  up  approximately  5-10%  of  the 
normal prostate gland. The transition zone lies on either side of the 
proximal  prostatic  urethra  lateral  to  the  internal  sphincter. 
Approximately 20% of  cases arise in the transition zone.
Periurethral glands
The periurethral glands comprise less than 1% of the glandular 
tissue. Anterior fibromuscular stroma
The  anterior  part  of  the  prostate  is  composed  mainly  of 
fibromuscular  stroma,  which  is  continuous  with  detrusor  fibres. 
Toward the apex of the gland, this fibromuscular tissue blends with 
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striated muscle from the levator. Puboprostatic ligaments also blend 
with this area.
Invaginated extraprostatic space
As  the  ejaculatory  ducts  enter  the  prostate  posteriorly,  an 
invaginated  extraprostatic  space  (IES)  surrounds  them  and 
invaginates  into  the  prostate.  The  IES  surrounds  the  ejaculatory 
ducts,  ends  at  the  verumontanum,  and  communicates  with  the 
periurethral  space.  In  1989,  Lee  first  introduced  the  concept  that 
invasion of the IES may be the first sign of extraprostatic extension of 
prostate cancer and an early sign of invasion of seminal vesicles22. In 
2005,  Amin  et  al  evaluated  the  pathological  significance  of  the 
invasion of IES in 80 patients with prostate cancer and concluded that 
IES involvement was consistently seen in cases with seminal vesicle 
invasion.23 
Bladder neck and the internal sphincter
The internal sphincter runs from the bladder neck to the level of 
the verumontanum. The smooth muscle fibres of the sphincter are 
continuous with the superficial layer of the trigone. In healthy males, 
the bladder neck and the internal sphincter are closed. In males with 
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a neurogenic bladder, the bladder neck and the prostatic urethra are 
wide  open,  and  some  investigators  have  used  transrectal 
ultrasonography (TRUS) to monitor the lower urinary tract in patients 
with spinal injuries. 
Pathophysiology and Natural History of prostate cancer25
Pathophysiology 
Prostate cancer develops when the rates of cell  division and 
cell death are no longer equal, leading to uncontrolled tumour growth. 
Following  the  initial  transformation  event,  further  mutations  of  a 
multitude of genes, including the genes for p53 and retinoblastoma, 
can lead to tumour progression and metastasis. Most (95%) prostate 
cancers are adenocarcinomas arising from the prostatic gland acini.
Approximately 4% of cases of prostate cancer have transitional 
cell morphology and are thought to arise from the urothelial lining of 
the prostatic urethra. Few cases have neuroendocrine morphology. 
When present,  they are believed to arise from the neuroendocrine 
stem  cells  normally  present  in  the  prostate  or  from  aberrant 
differentiation programs during cell transformation.
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Of prostate cancer cases, 70% arise in the peripheral zone, 15-
20% arise in the central zone, and 10-15% arise in the transitional 
zone.  Most  prostate  cancers  are  multifocal,  with  synchronous 
involvement of multiple zones of the prostate, which may be due to 
clonal and nonclonal tumours.
Natural history
The natural history is still relatively unknown, and many aspects 
of progression are poorly understood. Symptoms or abnormal DRE 
findings  in  the  pre-PSA era  brought  only  40-50% of  patients  with 
prostate cancer to medical attention, and these patients usually had 
locally advanced disease. The advent of PSA testing has helped to 
identify patients with less-advanced, organ-confined disease.
In  fact,  the  pendulum  has  shifted  to  the  point  that  certain 
members of the urologic community feel that active surveillance, also 
known  as  expectant  management,  may  have  a  role. Twenty-year 
outcome data from Connecticut  confirm that  mortality rates due to 
tumours with a Gleason score of 2-4 was less than 7%.25 Urologists 
at Johns Hopkins University advocate active surveillance in patients 
with a PSA density of less than 0.1 ng/mL, with no adverse pathologic 
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findings on needle biopsy, and with tumours with a Gleason score of 
6 that are smaller than 3 mm.
Evidence suggests  that  most  prostate  cancers  are  multifocal 
and  heterogeneous.  Cancers  can  start  in  the  transitional  zone or, 
more commonly, the peripheral zone. When these cancers are locally 
invasive, the transitional-zone tumours spread to the bladder neck, 
while the peripheral-zone tumours extend into the ejaculatory ducts 
and seminal vesicles. Penetration through the prostatic capsule and 
along the perineural or vascular spaces occurs relatively late.
The  mechanism for  distant  metastasis  is  poorly  understood. 
The cancer  spreads to  bone early,  occasionally  without  significant 
lymphadenopathy.  Currently,  2  predominant  theories  have  been 
proposed for spread—the mechanical theory and the seed-and-soil 
theory.  The  mechanical  theory  involves  direct  spread  through  the 
lymphatics  and  venous  spaces  into  the  lower  lumbar  spine. 
Advocates of the seed-and-soil theory believe that tissue factors that 
allow for  preferential  growth  in  certain  tissues,  such  as the bone, 
must be present. Lung, liver, and adrenal metastases have also been 
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documented. Specific tissue growth factors and extracellular matrices 
are possible examples.
The  doubling  time  in  early-stage  disease  is  as  slow as  2-4 
years,  but  this  changes as  the  tumour  grows and becomes more 
aggressive. Larger tumours usually have a higher Gleason grade and 
a faster doubling time.
Natural history by stage
T1a - Progression over 10 years (uncommon) 
T1b - Tumour-related death rate of 10% in 10 years 
T2 - Ten-year metastasis-free survival rate of 81% with grade 1, 58% 
with grade 2, and 26% with grade 3 
T3  -  Lymph  node  metastasis  at  presentation  in  50%  and 
approximately 25% rate of 10-year disease-free survival
The natural  history of  clinically localized disease varies,  with 
lower-grade  tumours  having  a  more  indolent  course,  while  some 
high-grade  lesions  progress  to  metastatic  disease  with  relative 
rapidity.  Several  studies  have  examined  the  cancer-specific  and 
quality-of-life outcomes associated with a watchful-waiting approach 
to localized disease. Albertsen et al monitored patients who received 
no  initial  treatment  for  prostate  cancer.25 As  disease  progression 
occurred,  many  received  anti-androgens.  Men  with  poorly 
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differentiated  tumours  lost  6-8  years  of  life,  while  those  with 
moderately  differentiated  tumours  lost  4-5  years.  Of  all  men 
monitored  for  10  years,  40%  died  of  causes  other  than  prostate 
cancer. This study was performed prior to PSA screening. 
Graversen  et  al  compared  watchful  waiting  with  radical 
prostatectomy.26 They found no overall difference in survival, but they 
did find that a high Gleason score was associated with poor survival 
in both groups. Chodak et al confirmed this finding by analyzing 6 
studies  and  finding  a  34%  survival  rate  associated  with  grade  3 
tumours versus an 87% disease-specific survival rate associated with 
grade  1  and  2  tumors.27 The  metastasis-free  survival  rate  also 
significantly dropped as the grade progressed from 1 to 3. 
Johansson  et  al  (2004)  reported  their  recent  update  on  a 
population-based cohort study with a mean observation period of 21 
years28. Prostate cancer specific mortality increased from 15 deaths 
per 1000 person-years during the first 15 years to 44 deaths per 1000 
person-years beyond 15 years of follow-up.
Taken together, these data suggest that, although most prostate 
cancers diagnosed at an early stage have an indolent course, local 
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tumour progression and aggressive metastatic disease may develop 
in  the  long  term.  In  addition,  these  findings  would  support  early 
radical  treatment,  notably  among  patients  with  an  estimated  life 
expectancy exceeding 15 years.
Detection of prostate cancer
The  histologic  diagnosis  of  prostate  cancer  is  made,  in  the 
majority of cases, by prostate needle biopsy. Prostate cancer rarely 
causes symptoms until it is advanced. Although there is controversy 
regarding the benefits of early diagnosis, it has been demonstrated 
that an early diagnosis of prostate cancer is best achieved using a 
combination of DRE and PSA. Transrectal ultrasound (TRUS)-guided, 
systematic needle biopsy is the most reliable method, at present, to 
ensure accurate sampling of prostatic tissue in men considered at 
high risk for  harbouring prostatic cancer on the basis of DRE and 
PSA findings.
The  presence  of  systemic  symptoms (e.g.,  bone  pain,  renal 
failure,  anaemia)  as  a  result  of  prostate  cancer  suggests  locally 
advanced or widely metastatic  disease.  Growth of  prostate cancer 
into  the  urethra  or  bladder  neck  can  result  in  obstructive  (e.g., 
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hesitancy,  decreased  force  of  stream,  intermittency)  and  irritative 
(e.g.,  frequency,  nocturia,  urgency,  urge  incontinence)  voiding 
symptoms. Impotence can be a manifestation of prostate cancer that 
has spread outside the prostatic capsule to involve the branches of 
the pelvic plexus (neurovascular bundle)
The routine use of DRE and PSA testing in asymptomatic men 
as a means of reducing prostate cancer mortality by earlier detection 
and treatment remains controversial 29, 30.
The U.S.  Preventive Services Task Force concluded that  the 
evidence is insufficient to recommend for or against routine screening 
for prostate cancer using PSA testing or DRE. The American Cancer 
Society  20 and  the  American  Urological  Association  recommended 
that prostate cancer screening with PSA and DRE be offered to all 
men older than 50 years and that the risks and benefits of screening 
be discussed with the patient.
The PLCO trial  was  designed to address whether  or  not  screening 
reduced  prostate  cancer  mortality  given  the  practices  of  diagnosis  and 
treatment in the community. Follow-up biopsies for a positive screen and 
specific treatments for prostate cancer are not mandated in this trial. Pinsky 
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et al  reported low follow-up biopsy rates after a positive screen in the PLCO 
trial, and whether this will compromise the ability of the trial to demonstrate 
a screening effect is controversial. 31 The PLCO has a calculated power of 
90% to show a mortality reduction of 20% in the screened population if the 
compliance rate is 90% and the contamination rate is 20% 32
In the ERSPC, recruitment of 165,000 men to the core age group of 
55 to 69 years will have a power of 86% to show a 20% to 25% mortality 
reduction in 2008 if the contamination rate is 20% 32
Digital Rectal Examination 
Before  the  availability  of  PSA testing,  physicians  relied  solely  on 
DRE for early detection of  prostate  cancer.  DRE is  a test  with only fair 
reproducibility even in the hands of experienced examiners that misses a 
substantial  proportion  of  cancers  and  detects  most  cancers  at  a  more 
advanced pathologic stage, when treatment is less likely to be effective. 9 In 
both screened and unscreened populations, DRE misses 23% to 45% of the 
cancers that are subsequently found with prostatic biopsies done for serum 
PSA  elevations11.  Results  from  a  randomized  trial  of  prostate  cancer 
screening demonstrated that DRE alone resulted in detection of 56% of 473 
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cancers, and 17% of the 473 cancers would have been missed by PSA-based 
screening alone. 33
PSA improves  the positive  predictive  value (i.e.,  the  proportion of 
men with a positive test who actually have disease) of DRE for cancer. The 
positive predictive value of DRE in contemporary series increases directly 
with the PSA level. The positive predictive value of DRE also depends on 
age and race 33. In a screened population of men with suspicious DREs and 
PSA levels less than 4 ng/mL, Carvalhal and colleagues34 found that black 
race  and  older  age  were  associated  with  higher  cancer  detection  rates. 
Schroder and associates evaluated a screened population and found that the 
positive predictive value of DRE ranged from 4% to 11% in men with PSA 
levels of 0 to 2.9 ng/mL and from 33% to 83% in men with PSA levels of 3 
to 9.9 ng/mL or more. 33 
Some  investigators  have  suggested  that  the  value  of  DRE  for 
screening at PSA levels below 3.0 ng/mL is limited. However, because of the 
risk  of  prostate  cancer  among  men  with  abnormalities  on  DRE and  the 
simplicity of the examination, most urologists use PSA and DRE together 
for prostate cancer detection. 33 
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Prostate-Specific Antigen (PSA or hK3) 
The most notable marker in the evaluation of prostate cancer is hK3, 
also known as PSA. It was first identified and purified in the late 1970s, but 
widespread use in clinical urology did not occur for another decade. 35, 36 PSA 
is a 33-kD glycoprotein that acts as a serine protease. The ectopic expression 
of PSA has been reported in smaller concentrations in the tissue of malignant 
breast tumours, normal breast tissue, female serum, and adrenal and renal 
carcinomas36;  however,  for  practical  and  clinical  purposes  PSA is  organ 
specific,  primarily  produced  by  the  prostatic  luminal  epithelial  cells. 
Although it is organ specific, PSA is not cancer specific, as demonstrated by 
the substantial overlap in values between men with benign versus malignant 
prostatic diseases. 37
The function of this androgen-regulated protease is to liquefy semen 
through its action on the gel-forming proteins semenogelin and fibronectin 
within the semen following ejaculation  38.  PSA is normally found in low 
concentration in sera (ng/mL). Within sera, PSA circulates in both bound and 
unbound  forms.  Most  PSA  in  sera  is  bound  or  complexed  to  the 
antiproteases (ACT) and macroglobulin (MG) 38.  Binding of free PSA to 
ACT  inactivates  the  protease,  but  the  complex  PSA-ACT  remains 
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immunodetectable by current assays  38. Binding of PSA to MG still allows 
some proteolytic activity but renders the PSA-MG complex undetectable by 
most  current  assays  38.  Free PSA without  proteolytic  activity  is  probably 
rendered inactive within the prostatic epithelial cell before release into the 
sera. This free inactive PSA does not form complexes with antiproteases, 
circulates unbound in sera, and is immunodetectable by current assays. The 
concentrations  found  in  seminal  plasma  range  from  0.5  to  5.0  mg/mL, 
whereas the normal serum concentration in men aged 50 to 80 years without 
prostatic disease ranges between 1.0 and 4.0 ng/mL 39. 
PSA is probably cleared from the blood through the liver as the size of 
the complexed structure is  too large  for  glomerular  filtration.  The serum 
half-life of PSA, calculated after removal of all  prostate tissue,  is 2 to 3 
days. 36 Uncomplexed PSA is cleared from the serum within 2 to 3 hours and 
is probably excreted by the kidney because of its smaller size  or cleared as a 
result of formation with new complexes with antiproteases.
Prostate  cancer  cells  do  not  necessarily  make  more  PSA than  do 
normal  prostate  cells,  and elevated  serum levels  are  probably a  result  of 
cancer  progression  and  destabilization  of  the  prostate  histologic 
architecture36   
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PSA expression is strongly influenced by androgens. In men without 
BPH, the rate of change in PSA is 0.04 ng/mL per year, compared with 0.07 
to 0.27 ng/mL per year in men with BPH who are between the ages of 60 
and 85 years. 40 
The  loss  of  the  barrier  afforded  by  the  basal  layer  and  basement 
membranes  within  the  normal  gland can occur  in  the  setting  of  prostate 
disease (BPH, prostatitis,  prostate cancer) and with prostate manipulation 
(prostate  massage,  prostate  biopsy) 36.  Prostatic  inflammation  (acute  and 
chronic) and urinary retention can cause PSA elevations to variable degrees. 
Prostatic trauma such as occurs after prostatic biopsy can result in a leak of 
PSA into the circulation that may require more than 4 weeks for return to 
baseline values. Even DRE as performed in an outpatient setting can lead to 
increases in serum PSA. 
Prostate-directed  treatment  (for  both  BPH  and  cancer)  can  lower 
serum PSA by decreasing the volume of prostatic epithelium available for 
PSA production and by decreasing the amount of PSA produced per cell. 
Manipulation of the hormonal environment for treatment of cancer and BPH 
can  lead  to  reductions  in  serum PSA.  Finasteride  (5  mg)  and  other  5α-
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reductase inhibitors for treatment of BPH have been shown to lower PSA 
levels by an average of 50% after 6 months of treatment41. 
Clinical Use of Serum Prostate-Specific Antigen Levels 
Early  studies  established the reference  range of  0  to  4.0 ng/mL to 
define normal serum PSA levels. This level was obtained using the Tandem-
R PSA assay (Hybritech, San Diego, CA) among a cohort of healthy men 
and demonstrated that healthy men 40 years old and younger and 97% of 
men older than 40 years have PSA levels equal to or less than 4.0 ng/mL. 
Although the PSA threshold of 4 ng/mL has been most commonly used, the 
PSA threshold that most efficiently balances the dual goal of reducing cancer 
mortality  and  reducing  unnecessary  testing  (PSA  measurements  and 
biopsies) is not known. Many studies have made an effort to evaluate other 
thresholds to maximize the positive biopsy rate of PSA-based screening. 
Gann  and  co  workers  42  evaluated  the  ability  of  a  single  PSA 
measurement to predict the later development of prostate cancer among men 
and found that the maximum validity occurred at a PSA threshold of 3.3 
ng/mL. Determination of sensitivity and specificity at given PSA thresholds 
does not provide information on the biologic characteristics of the cancers 
detected.
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Using a single cut off  PSA value for all men may risk exclusion of an 
unacceptably high number of patients with clinically significant early-stage 
disease;  some  men  with  PSA values  less  than  4.0  ng/mL may  harbour 
clinically  significant  organ-confined  cancer.  Catalona  and  associates 
detected  prostate  cancer  in  22%  (73  of  332)  of  a  group  of  men  who 
underwent biopsy at PSA levels of 2.6 to 4.0 ng/mL and had benign prostate 
examinations. 43
Early  studies  recognized that  the  positive  predictive  value  of  PSA 
testing for cancer detection increased from 12% to 32% for PSA levels of 4 
to 10 ng/mL and as high as 60% to 80% for levels above 10 and 20 ng/mL 43 
Thus, men with PSA levels greater than 10 ng/mL and benign DRE have up 
to  a  60% likelihood of  being diagnosed with  cancer  and are  unlikely  to 
benefit from further improvement of PSA sensitivity and specificity. These 
percentages are even more pronounced for levels greater than 20 ng/mL or 
when DRE is suspicious for prostate cancer7. 
For men with PSA levels between 4 and 10 ng/mL, and more recently 
2.5  to  10  ng/mL,  the  specificity  of  cancer  detection  has  been  more 
challenging. Cancers discovered within this range are often earlier in stage, 
and  potentially  more  curable,  yet  might  also  represent  “insignificant,” 
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potentially non–life-threatening tumours. 
Transrectal Ultrasonography Technique
Preparation, positioning, and contraindications
More  than  80%  of  urologists  administer  an  enema  prior  to 
transrectal  ultrasonography (TRUS) and prostate biopsy,  but  some 
authors feel this is unnecessary.
More  than  90%  of  urologists  administer  oral  agents  for 
prophylactic antibiotic coverage. A total of 11 different antibiotics with 
20 different dosages and durations of treatment, ranging from 1-17 
days, have been reported. Increasing support has been garnered for 
single-dose  prophylaxis  in  patients  with  uncomplicated  medical 
conditions. A fluoroquinolone antibiotic prior to the procedure and a 
second  dose  12  hours  later  is  the  protocol  most  commonly 
recommended  for  antibiotic  coverage.  In  patients  with  prosthetic 
implants or valvular heart disease, additional prophylaxis with 1 g of 
intramuscular ampicillin (or 1 g IV vancomycin in patients who are 
allergic  to  penicillins)  and  80  mg  of  intramuscular  gentamicin  is 
recommended.
Positioning can be either left lateral, lithotomy, or knee-elbow.
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Contraindications  to  biopsy include an  acute  painful  perianal 
disorder and hemorrhagic diathesis. Patients should be discouraged 
from taking  aspirin  or  non-steroidal  anti-inflammatory drugs for  10 
days prior to the procedure, but recent use should not be considered 
an absolute contraindication to biopsy.
Local anaesthesia and the procedure
Although the procedure was performed without any infiltrative 
anesthesia  in  the  past  it  is  a  common  practice  to  use  lidocaine 
infiltration in the periprostatic area.  In 2001, Pareek et al described a 
technique of periprostatic nerve blockade.44 They injected 2.5 ml of 
lidocaine on each side at  the prostate base at  the junction of  the 
prostate and the seminal vesicle (using a 5-in 22-gauge spinal needle 
through  the  ultrasound  probe).  In  a  randomized,  double-blind, 
placebo-controlled study, they showed significant pain control during 
and  after  biopsy.  Alavi  et  al  compared  the  efficacy  of  intrarectal 
lidocaine gel with that of periprostatic nerve block and concluded that 
the nerve block was superior for pain control. Using this technique, 
saturation biopsies, with up to 20 cores, could be performed.
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In 2005, Mutaguchi et al reported a comparison of 2 techniques 
of  local  anesthesia  for  prostate  biopsy.45 In  the periprostatic  block 
technique, 5 ml of 1% lidocaine was injected via a 7-in,  22-gauge 
spinal  needle into  the region of  the prostatic  vascular  pedicle  just 
lateral  to  the  junction  of  seminal  vesicles  and  the  prostate.  The 
needle is slowly withdrawn to the prostatic apex, and an additional 5 
ml  of  lidocaine  is  injected  at  the  apex.  In  the  intraprostatic  block 
technique, 10 ml of 1% lidocaine was injected into 2-3 sites of each 
prostate lobe. In this study, the intraprostatic block provided superior 
pain control during the prostate biopsy.
Technique of TRUS of prostate
Currently,  the most widely used probe is a 7-MHz transducer 
within an endorectal probe, which can produce images in both the 
sagittal and axial planes. Scanning begins in the axial plane, and the 
base of the prostate and seminal vesicles are visualized first. A small 
amount of urine in the bladder facilitates the examination. Seminal 
vesicles  are  identified  bilaterally,  with  the  ampullae  of  the  vas  on 
either side of the midline. The seminal vesicles are convoluted cystic 
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structures that are darkly anechoic. Men who have abstained from 
ejaculation for a long period may have dilated seminal vesicles.
Next, the base of the prostate is visualized. The central zone 
comprises the posterior part of the gland and is often hyperechoic. 
The mid gland is the widest portion of the gland. The peripheral zone 
forms most of the gland volume. Echoes are described as isoechoic 
and closely packed.  The transition zone is  the central  part  of  the 
gland and is hypoechoic. The junction of the peripheral zone and the 
transition  zone  is  distinct  posteriorly  and  is  characterized  by  a 
hyperechoic  region,  which results  from prostatic  calculi  or  corpora 
amylacea.  The  transition  zone is  often filled  with  cystic  spaces in 
patients with benign prostatic hyperplasia (BPH).
Scanning at the level of the verumontanum and observing the 
Eiffel tower sign (anterior shadowing) help to identify the urethra and 
the  verumontanum.  The  prostate  distal  to  the  verumontanum  is 
composed  mainly  of  the  peripheral  zone.  The  capsule  is  a 
hyperechoic structure that can be identified all  around the prostate 
gland.  Several  hypoechoic  rounded  structures  can  be  identified 
around the prostate gland. These are the prostatic venous plexi. The 
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position of the neurovascular bundles can often be identified by the 
vascular structures. Imaging in the sagittal plane allows visualization 
of the urethra. The median lobes of the prostate are often visualized.
Volume measurement
Volume assessment of the prostate is an important and integral 
part of this procedure. Several formulas have been used, the most 
common  of  which  is  the  ellipsoid  formula,  which  requires 
measurement  of  3  prostate  dimensions.  Dimensions  are  first 
determined  in  the  axial  plane  by  measuring  the  transverse  and 
anteroposterior dimension at the estimated point of widest transverse 
dimension.  The  longitudinal  dimension  is  measured  in  the  sagittal 
plane just off the midline because the bladder neck often obscures 
the cephalad extent of the gland. The ellipsoid volume formula is then 
applied, as follows: 
Volume = height X width X length X 0.52
Biopsy
Biopsies are best performed with a spring-driven needle core 
biopsy device  (or  biopsy  gun),  which  can  be  passed  through  the 
needle guide attached to the ultrasound probe. Most instrumentation 
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provides optimal visualization of the biopsy needle path in the sagittal 
plane. In general,  18-gauge needles are used, and the tips of the 
needles are etched with small  ridges or  pits  to render  them more 
echogenic.  Sonograms  should  be  superimposed  with  a  ruled 
puncture trajectory that corresponds to the needle guide of the probe, 
which allows anticipation of the needle path.
Directed  biopsies  are  obtained  from  any  area  deemed  as 
suggestive (i.e., hyperechoic) based on ultrasonographic findings or 
based  on  palpable  abnormalities  after  digital  rectal  examination. 
Because the incidence of nonpalpable isoechoic prostate tumours is 
high,  limiting biopsy sites to either ultrasonographically hypoechoic 
lesions  or  to  areas  of  palpable  abnormality  tends  to  miss  many 
malignancies.
Obtaining separate biopsy samples from each sextant  of  the 
prostate,  improves  the  odds  of  sampling  clinically  inapparent 
tumours.  Originally,  these  biopsy  sites  included  the  midlobe 
parasagittal  plane  at  the  apex,  the  mid  gland,  and  the  base, 
bilaterally. Many authors subsequently recommended that (1) these 6 
biopsy samples be obtained from the lateral third of each lobe rather 
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than  from  the  mid  lobe  or  that  (2)  2  lateral  biopsy  samples  be 
obtained from each lobe in addition to the original sextant samples 
(termed the 10-biopsy scheme).  Obtaining even larger numbers of 
biopsy cores has been recommended by some authors to increase 
the diagnostic sensitivity.
Complications  of  prostate  biopsy  include  hematuria,  rectal 
bleeding,  hematospermia,  urosepsis,  and  perineal  pain.  Although 
most  of  these  complications  subside  within  48-72  hours,  patients 
should be warned that hematospermia can last for 3-4 weeks. In rare 
cases  (<1%), patients  develop  bacteremia  that  requires 
hospitalization  and  administration  of  intravenous  antibiotics.
Indications for Prostate Biopsy 
Before  TRUS  improvements  and  serum  PSA  testing  became 
widespread,  clinicians  relied  mainly  on  digital  rectal  examination  to 
establish  a  suspicion  of  prostate  cancer  and  performed  digitally  directed 
lesional  biopsies.  Today,  PSA-based  screening  of  asymptomatic  men  has 
resulted in the adaptation of TRUS biopsy as the standard of care for routine 
prostate biopsy. The presence of focal nodules on digital rectal examination 
still  will  prompt  a  biopsy  using  the  TRUS technique  regardless  of  PSA 
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levels.  TRUS-directed prostate needle biopsy remains the gold standard for 
diagnosis of prostate cancer. 
Early prostate cancer detection has been markedly improved by PSA-
based  screening  programs.  These  initiatives  have  been  shown  to 
significantly  increase  the  rate  of  organ-confined,  and potentially  curable, 
disease46.  Currently,  most  clinicians  recommend  biopsy  once  a  patient's 
serum PSA rises above 4.0 ng/mL, although significant research efforts are 
ongoing to identify the optimal PSA threshold to recommend prostate biopsy 
in the asymptomatic patient. Evidence for lowering the PSA threshold from 
work by Catalona's group showed higher rates of organ-confined disease at 
the time of radical retropubic prostatectomy in men sampled with PSAs in 
the 2.6- to 4.0-ng/mL range47.  These findings have led many urologists to 
now recommend prostate biopsy to men younger than 60 years of age once 
their PSA level rises above 2.5 ng/mL. Despite this downward shift in the 
PSA cut off for younger men, there remains a general trend toward allowing 
older men (70 years or older) to have slightly higher “normal” PSAs, in the 
range of 5.5 to 6.5 ng/mL, although this is not universally accepted.48
Adjuncts to serum PSA testing include measuring the free: total PSA, 
PSA velocity,  PSA density  (PSAD),  and  PSAD  of  the  transition  zone 
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(PSAD-TZ)  49. For patients with a serum PSA value between 4.0 and 10.0 
ng/mL, using a percentage of free PSA threshold of less than 25% detected 
95% of cancers while eliminating 20% unnecessary biopsies, and within this 
group the risk of prostate cancer increased dramatically as the percentage of 
free PSA level declined. 50
Regardless of initial PSA value, a PSA velocity greater than 0.75 to 
1.0  ng/mL  per  year  is  frequently  associated  with  prostate  cancer  and 
warrants  biopsy 49,  whereas  an  elevated  PSAD and PSAD-TZ have both 
been  shown  to  increase  the  likelihood  of  diagnosing  prostate  cancer  on 
repeat biopsy. 
Contraindications to Prostate Biopsy 
Significant  coagulopathy,  painful  anorectal  conditions,  severe 
immunosuppression,  and  acute  prostatitis  are  all  contraindications  to 
prostate biopsy.
Sextant Biopsy 
The original sextant biopsy scheme (one core from the base, mid, and 
apex  bilaterally)  significantly  improved  cancer  detection  over  digitally 
directed biopsy of palpable nodules and ultrasound-guided biopsy of specific 
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hypoechoic lesions 51. Taken in the parasagittal plane these cores sampled a 
portion of the PZ but also included a significant amount of tissue from the 
TZ,  with  subsequent  studies  of  radical  prostatectomy  specimens 
demonstrating  that  the  vast  majority  of  adenocarcinomas  arise  in  the 
posterolateral  PZ52,  thus  explaining  some  of  the  false-negative  results  of 
standard sextant biopsy.
Extended Core Biopsy Techniques 
Modifications to the standard sextant biopsy scheme have focused on 
the  importance  of  laterally  directed  cores 53.  Numerous  groups  have 
published series showing improved cancer detection rates by incorporating 
additional  laterally  directed  cores  into  the  standard  systematic  sextant 
technique,  ultimately  taking  anywhere  from 8  to  13  cores  13,  54,  49.  In  a 
prospective study of 483 patients Presti and coworkers  30found that adding 
laterally directed cores from the base and mid gland bilaterally improved 
cancer detection from 80% with standard sextant to 96% with this 10-core 
scheme (only  4% of  cancers  were  detected  on the lesion directed or  TZ 
biopsy).  At present, 6 cores are considered inadequate for routine prostate 
biopsy for cancer detection. 
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Increasing Prostate Cancer Detection Rates with Extended Core 
Biopsy Protocols 
TZ and SVs are  not  routinely sampled because these regions have 
been shown to have consistently low yields for cancer detection at initial 
biopsy, 55,56 but TZ and anteriorly directed biopsies may occasionally prove 
necessary  to  diagnose  prostate  cancer  in  those  patients  with  persistently 
elevated PSA levels and prior negative biopsies57. However, there may be a 
role for TZ biopsies in men with gland size of more than 50 ml, with an 
additional yield of 15% cancer detection in these larger prostates 58. Seminal 
vesicle  biopsy  is  not  routinely  performed  unless  there  is  a  palpable 
abnormality,  with some authors recommending SV biopsy when the PSA 
value is greater than 30 or if brachytherapy is being considered. 
Study Cores Detection rate
Eskew et al, 1997 59
6 26.1%
13 40.3%
Naughton et al, 2000 60
6 26%
12 27%
Presti et al, 2000 13 6 33.5%
8 39.7%
10 40.2%
Babaian et al, 2000 61 6 20%
11 30%
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Repeat and Saturation Prostate Biopsy 
Physicians  are  frequently  presented  with  the  dilemma  of  a 
patient  who  has  had  one  or  more  negative  prostate  biopsies  yet 
continues to have an elevated PSA value or abnormal digital rectal 
examination of concern for prostate cancer. Often these patients have 
undergone multiple biopsies despite the well-documented decline in 
cancer  detection  with  each  successive  biopsy  62.  Keetch  and 
coworkers  63 reported an initial positive biopsy rate of 34% in 1136 
men  from  their  PSA-based  prostate  cancer  screening  program. 
Cancer detection rates then fell to 19%, 8%, and 7% on biopsy 2, 3, 
and 4, respectively.  These findings were confirmed by results from 
the European Prostate Cancer Detection Study. In this cohort of 1051 
men with PSA values between 4.0 and 10.0 ng/mL the initial cancer 
detection rate with sextant biopsy was 22%. Positive cores were then 
found in only 10%, 5%, and 4% of patients on subsequent biopsies 2, 
3, and 462 
These  diminishing  returns  coupled  with  improved cancer  detection 
rates  on  initial  biopsy  with  extended  core  protocols  have  led  some 
researchers to examine “saturation biopsy” techniques in this difficult subset 
42
of patients.  In a study of 57 men with an average of two prior  negative 
sextant  biopsies,  a  cancer  detection  rate  of  30%  was  obtained  with  an 
average of 22.5 cores per patient 64. Similar protocols from the Mayo Clinic65 
demonstrated  improved  cancer  detection  rates.  A  drawback  to  these 
techniques  is  that  additional  anesthetic  requirements  often  require  these 
“saturation” biopsies to be performed in a hospital setting. 
Ramey et al, suggested that equally improved cancer detection rates 
can be achieved in this setting utilizing contrast medium–enhanced TRUS 
(CE-TRUS) and a targeted biopsy protocol in an outpatient setting with only 
10  cores  66,  thereby  minimizing  the  morbidity  and  costs  associated  with 
saturation  biopsies.  The  use  of  the  free  and  total  PSA may  also  allow 
classification of patients into low probability or high probability of having 
prostate cancer with a PSA level less than 10 ng/mL and determine the need 
for additional prostate biopsy after an initial negative result 50
Advanced ultrasonographic techniques for prostate imaging 
Colour and Power Doppler TRUS 
Colour  Doppler  imaging  is  based  on  the  frequency  shift  in  the 
reflected sound waves from the frequency of insonation and thus depicts the 
velocity  of  blood  flow  in  a  directionally  dependent  manner.  Colour 
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assignment is based on the direction of blood flow related to the orientation 
of the transducer receiving the signal; flow toward the transducer is depicted 
in shades of red and flow away in shades of blue; the colour is not specific 
for arterial or venous flow. Power Doppler imaging (also known as enhanced 
colour  Doppler,  colour  amplitude  imaging [CAI],  or  colour  angiography) 
utilizes  amplitude  shift  to  detect  flow  in  a  velocity  and  directionally 
independent manner  67.  The advantages of power Doppler imaging are its 
ability to detect slower flow and to have less reliance on the Doppler angle, 
making  it  more  suitable  for  detection  of  prostate  cancer  neovascularity. 
Although  power  Doppler  imaging  offers  improved  sensitivity  to  small 
amounts of flow, neither modality has yet proved itself superior to the other 
for cancer detection.
In a study by Maruzzi et al, 68 222 biopsies performed on 71 
patients between 1997 and 1999 were considered, which led to a 
diagnosis of neoplasm in 36 patients. Of the 84 biopsies that revealed 
prostate adenocarcinoma, 74 (64.3%) were correlated to hypoechoic 
lesions with abnormal flow signals while 41 (35.6%) showed a benign 
pathology (prostatitis or benign prostatic hyperplasia) (p < 0.0011). In 
five patients (13%) who did not present any evident lesions at a first 
transrectal  ultrasound,  the  diagnosis  of  neoplasm was  made  only 
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through biopsies targeted on areas with abnormal  flow.  Therefore, 
they concluded that  the colour  Doppler  exam can be used during 
prostate ultrasonography either to consolidate the diagnosis or to give 
a useful target in case of isoechoic lesions. 
 Takahashi and colleagues69  studied a total of 108 men (mean 
age 67.7 years, range 50 to 86) with serum PSA levels of greater 
than  4.0  ng/mL using  digital  rectal  examination  (DRE),  grey-scale 
transrectal ultrasonography (TRUS), and PDUS  and systematic six-
core transperineal biopsy and additional biopsies for positive sites on 
DRE, grey-scale TRUS, and PDUS. A hypervascular site and prostate 
cancer on PDUS was identified in 43 (40%) and 40 (37%) cases, 
respectively.  The sensitivity of PDU for cancer detection was 90%, 
specificity  90%,  positive  predictive  value  84%,  negative  predictive 
value  94%  and  accuracy  90%.  High  test  performance  was  also 
observed in  53 cases  with  serum PSA levels  of  4.1  to  10  ng/mL 
(sensitivity  77%,  specificity  88%,  positive  predictive  value  67%, 
negative  predictive  value  92%,  and  accuracy 85%).  These values 
were superior or comparable to those of DRE and grey-scale TRUS. 
Inflammatory  reactions  and  prostatic  calculi  were  probable  major 
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causes  of  false-positive  and  false-negative  results  on  PDUS, 
respectively. 
Okihara et al70  studied 275 men. Cancer was identified in 27% 
of men in Japanese and in 60% of American men. The sensitivity and 
specificity of PDI in Americans were significantly inferior to those in 
Japanese.  The  negative  predictive  value  (NPV)  of  PDI  was 
significantly higher for Japanese. 
In a significant study by Wilson et al, 71  96 patients with LUTS 
and PSA > 4 ng/ml were evaluated using PDUS before biopsy. There 
was a significant  correlation between the grading system used for 
power  Doppler  and  the  microvessel  density  (MVD;  PZ0  28.61  +/- 
8.97, PZ1 36.00 +/- 12.11 & PZ2 64.008 +/- 15.86; p < 0.001). There 
was also a significant difference in MVD between benign, malignant 
and tissue cores with atypia and prostatic intra-epithelial  neoplasia 
(PIN; p < 0.001 and p < 0.018 respectively). There was a significant 
correlation between malignant tissue having a higher Gleason score 
and increased MVD (p < 0.001) Furthermore, cancer biopsies having 
a high flow PZ2 are nearly twice as likely (63.2%) to have a Gleason 
score of 7 or more when compared those having a Gleason score of 
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less  than  7  (36.8%).  They concluded that  it  can  be  useful  in  the 
detection of prostate cancer. 
In a study by Inahara et al, 72101 men with abnormal DRE or 
PSA were assessed with TRUS with PDI.  Of the 101 patients,  48 
(47.5%),  42  (41.5%)  and  42  (41.5%)  were  suspicious  of  having 
prostate  cancer  by DRE,  TRUS and  PDI,  respectively.  If  prostate 
needle  biopsy  was  avoided  when  PDI  was  negative,  then  PDI 
eliminated  the  need  for  biopsy in  59  of  the  101  patients  (rate  of 
biopsy procedures saved: 58.4%) and missed only 8 (13.6%) prostate 
cancers. Moreover, in 63 patients with intermediate PSA (3-10 ng/ml), 
the rate of biopsy procedures saved by DRE, TRUS, and PDI was 
60.3%,  65.1%,  and  68.3%,  respectively,  and  the  rate  of  cancers 
missed  was  26.3%,  19.5%,  and  14.0%,  respectively.  34.1%  of 
prostate cancer sites were isoechoic and hypervascular. On a site by 
site  basis,  PDI  had better  sensitivity,  specificity,  positive  predictive 
value and negative predictive value than TRUS. In patients without 
abnormal DRE findings, on a site by site basis, the sensitivities of 
TRUS and PDI were 22.9% and 34.4%, respectively. 
In a study by Remzi et al, 73136 men with PSA between 2.5 and 
10 ng/ml (mean age 64 +/- 9 years, range 45-82) and a normal DRE 
47
were included. 101 underwent a first biopsy whereas 35 had repeat 
biopsy. Overall prostate cancer detection rate was 34.7% and 25.7% 
and abnormal accumulation on PD-TRUS was identified in 42.3% and 
48.6% on  first  and  repeat  biopsy,  respectively.  PD-TRUS directed 
biopsies were positive in 5.7% and 11.1% on first and repeat biopsy 
whereas prostate cancer detection using the routine prostate biopsy 
regime  was  94.3%  and  88.9%  on  first  and  repeat  biopsy.  The 
sensitivity,  specificity,  positive  predictive  value  (PPV)  and negative 
predictive value (NPV) of PD-TRUS signal alone for prostate cancer 
detection  on  first  biopsy  was  82.8%,  78.8%,  87.9%  and  89.7%, 
respectively, and 88.8%, 68.0%, 47.0% and 94.4% on repeat biopsy, 
respectively. Negative PD-TRUS signal is able to exclude most of the 
patients without prostate cancer in the PSA range of 2.5-10 ng/ml. As 
an  additional  tool  at  TRUS biopsy PD-TRUS has  a  high negative 
predictive value and may help to reduce the number of unnecessary 
biopsies.
In a study by Satoru 74et al, 108 men with serum PSA levels of 
greater  than  4.0  ng/mL  were  assessed  using  DRE,  TRUS,  and 
PDUS.  A  hypervascular  site  and  prostate  cancer  on  PDU  was 
identified  in  43  (40%)  and  40  (37%)  cases,  respectively.  PDUS-
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directed and systematic six-core biopsies could independently detect 
36 and 30 cancer cases,  respectively.  The sensitivity of  PDUS for 
cancer detection was 90%, specificity 90%, positive predictive value 
84%,  negative predictive value 94% and accuracy 90%.  High test 
performance was also observed in 53 cases with serum PSA levels of 
4.1 to 10 ng/mL (sensitivity 77%, specificity 88%, positive predictive 
value  67%,  negative  predictive  value  92%,  and  accuracy  85%). 
These values were superior or comparable to those of DRE and gray-
scale  TRUS.  PDUS  can  identify  appropriate  sites  for  biopsy  and 
improve the cancer detection rate. Combined use of sextant biopsy 
and PDUS should be preferable.
Mohammd et  al75  in their  study concluded that,  Colour-coded 
Doppler  flow  within  the  tumor  and  overlying  capsule  appears  to 
correlate  with  both  tumor grade and stage,  respectively.  Detection 
and grading of colour-coded flow within biopsy-proven cancers may 
identify  patients  with  a  high  likelihood  of  biochemical  relapse. 
Tsuneyuki Nakanouchi et al76from their study on 22 patients prior to 
RP concluded  that, semi  quantitative  assessment  of  Doppler  flow 
signals using PDI appears to be of clinical value as an indicator of 
MVD. 
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Arger etal77  studied  90 patients and found that 71% of the 31 
focal  hypoechoic  lesions  were  hypervascular.  Only  23%  were 
carcinoma.  Sauvain78 et  al  studied  323  patients  with  suspected 
cancer. The sensitivity of PDS for prostatic cancer was 92.4% and its 
specificity was 72% (versus 87.9% and 57.6% for sonography alone 
respectively).  The  NPV  of  PDS  was  80.6%  (p<0.0001).  Targeting 
area presenting abnormal blood flow in any part of the prostate was 
useful  to  detect  isoechoic or  lesions in  patients with  first  negative 
biopsy results. 
Halpern et al79, in their study on 62 patients with cancer in 18 
(29%) patients found that The positive biopsy rate for targeted biopsy 
(24  [13%]  of  185  cores)  was  slightly  higher  than  that  for  sextant 
biopsy (36 [9.7%] of  372 cores;  P =.1).  The odds ratio for  cancer 
detection with targeted versus sextant cores was 1.8 (95% CI: 0.9, 
3.7).  Receiver  operating  characteristic  analysis  demonstrated  that 
overall  identification  of  positive  sextant  biopsy  sites  was  close  to 
random chance for grey-scale (area under the curve, 0.53), colour 
Doppler (area under the curve, 0.50), and power Doppler (area under 
the curve, 0.47) imaging. 
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Okihara  et  al80,  in  their  study  on  a  total  of  170  cases,  the 
positive biopsy rate was 59% (40/68) in cases with HVL, compared to 
1% (1/102) in cases with no HVL (p < 0.0001). In 107 patients with 
serum PSA 4.1 to 10.0 ng/ml, biopsy was positive in 13 cases (12%). 
The  positive  biopsy  rate  was  38%  (12/32)  in  cases  with  HVL, 
compared to 1% (1/75) in cases with no HVL (p < 0.0001). These 
results  imply  that  HVL represents  the  neovascularity  or  increased 
perfusion of blood in the cancer lesion. 
Sakarya et al81, in their study on 36 patients calculated that the 
sensitivity  of  PDU was  90%,  the  specificity  75% and  the  positive 
predictive value 82%. Okihara et al  82  in their study on 107 patients 
found that PDI had a high sensitivity of 98% (40/41) and a negative 
predictive  value  of  99%  (101/102).  PDI  could  save  a  significant 
number of patients from undergoing unnecessary biopsies, compared 
with  DRE  and  TRUS  (P  <  0.001).  28  patients  were  studied  by 
Franco83 and colleagues, and the sensitivity of PDUS was 74%, the 
specificity 96% and the positive predictive value 74%. 
Whereas Doppler modes showed an improved diagnosis versus grey-
scale  TRUS,  45% of  cancers  still  went  unidentified  by  any  sonographic 
51
modality. Others have shown increased cancer detection rates using Doppler-
targeted  biopsy  strategies  81,  but  none  is  sufficiently  accurate  to  replace 
systematic  biopsy  79.  Enhancements  in  the  technical  aspects  of  colour 
Doppler TRUS, including the use of contrast agents (see later), may provide 
the necessary improvements to specifically identify cancer sites in the future. 
Multiple studies have shown that angioneogenesis and the resultant 
increase  in  microvessel  density  that  occurs  within  foci  of  prostatic 
adenocarcinoma  correlates  with  the  presence  of  metastases84,  stage  of 
disease 84,85, and disease-specific survival. Interest in using colour and power 
Doppler  TRUS to aid in  prostate  cancer  detection stems from studies  of 
radical prostatectomy specimens demonstrating that foci of adenocarcinoma 
possess  an  increased density  of  microvessels  compared with surrounding 
normal parenchyma. 86  Patients with detectable colour Doppler flow within 
their dominant tumor at the time of TRUS-guided biopsy are at a 10-fold 
increased risk for PSA recurrence after radical retropubic prostatectomy  76 
The presence of  increased flow was also associated with higher Gleason 
grade, increased incidence of SV invasion, and a lower biochemical disease-
free  (bNED)  survival  rate  versus  subjects  without  increased  flow  on 
preoperative TRUS (50% vs. 96% bNED at 31 months). 
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Current Doppler modalities are not able to identify the microvessels of 
prostate  cancer,  which  are  typically  10  to  15  μm in  diameter.  The  flow 
signals associated with malignant foci detected by unenhanced colour and 
power  Doppler  imaging are  due to  detection  of  larger  feeding vessels. 88 
Intravenous  micro  bubble  ultrasound  contrast  agents,  similar  to  those 
currently  approved  and  used  in  echocardiography,  have  been  infused 
systemically during grey-scale and TRUS Doppler imaging to amplify flow 
signals within the microvasculature of prostate tumours, allowing selective 
visualization  of  malignant  foci  in  clinical  trials  79,  88.  These  intravenous 
“bubble” contrast agents are constructed with air or higher-molecular-weight 
gas agents encapsulated (albumin or polymer hard shell, lipid or surfactant 
coated) for longevity and are generally 1 to 10 μm. 
Using CE-TRUS for prospective prostate cancer detection, Halpern 
and associates79 demonstrated an increase in sensitivity from 38% to 65% 
versus  baseline  unenhanced  imaging,  without  significantly  altering 
specificity.  Subsequent  studies  by  our  group  and  others  have  improved 
sonographic  detection  of  malignant  foci  utilizing  CE-TRUS and targeted 
biopsy of enhancing lesions89, 90. Imaging using micro bubble contrast agents 
combined with three dimensional image reconstruction of enhanced power 
Doppler  images  also  demonstrated  increased  diagnostic  accuracy.  Future 
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developments  in  these  and  other  imaging  modalities  that  can  selectively 
visualize prostate cancers  based on the presence of angioneogenesis may 
ultimately allow more accurate localization of the sites of cancer. 
Other Investigational Techniques 
Artificial neural networks are another potential way to enhance TRUS 
images  and  identify  malignant  foci. Investigational  automated  image 
analysis, including pattern recognition and artificial neural networks applied 
to TRUS images, may successfully identify lesions that cannot be seen by 
the human eye. 91
A new sonographic technique known as elastography may prove to be 
superior to colour Doppler imaging in the identification of malignant areas 
in the prostate. 92 This technique employs real-time sonographic imaging of 
the prostate at baseline and under varying degrees of compression. Through 
computerized calculations,  differences in displacement  between ultrasonic 
images from baseline and during compression may be visualized and regions 
with decreased tissue elasticity may be tagged as suggestive of malignancy. 
In a  preliminary  study of  404 cases with 151 cases  positive for  prostate 
cancer, the malignancy was found in 127 patients (84.1%) with real-time 
elastography directing the biopsy. 93
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Endorectal magnetic resonance imaging (MRI) and MR spectroscopy 
as  combined  modalities  might  be  able  to  guide  and  therefore  limit  the 
number of iterative biopsies and cores for patients 94. Utilization of MRI will 
require  modifications  in  instrumentation  and  the  technique  of  biopsy  95. 
These MRI-directed biopsy techniques require expensive equipment that is 
not widely available for biopsy procedures.
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MATERIALS AND METHODS
A prospective study was conducted in the time period between 
August 2007 and October 2009. All the patients more than 50 years 
who  presented  to  the  Urology  OPD(out  patient  department)  with 
LUTS with abnormal digital rectal examination and/or PSA>=4 ng/ml 
were evaluated for inclusion in the study.
Exclusion criteria
1. No consent for study
2. Persistent urinary tract infection
3. Untreated coagulopathy
After obtaining informed consent all the patients were enrolled 
into  the  study.  Routine  clinical  evaluation  was  done  as  per  the 
proforma and the findings were recorded.
All the patients were evaluated by TRUS. On the day prior to 
the procedure, ciprofloxacin 500mg bd and metronidazole 400 mg tds 
was  prescribed,  which  was  continued  for  2  days  post  procedure. 
PC(proctoclysis)  enema  was  given  on  the  day  of  the  procedure. 
Intravenous pethidine was given as analgesic if  the patient did not 
tolerate pain.
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Patients  were  examined using  the  SSD2000 System (Aloka, 
Japan); PDUS was carried out with a Power Flow Unit and 7.5 MHz 
broadband endoluminal probe. The patients were examined in the left 
lateral decubitus position. All patients underwent greyscale TRUS of 
the entire prostate gland in the sagittal plane, from the right to left 
lateral aspects of the gland and in the axial plane from the seminal 
vesicles  to  the  apex.  The  size  and  weight  of  the  gland  were 
calculated  from  the  anteroposterior,  transverse  and  cranio  caudal 
measurements (0.52 × D1 × D2 × D3). 
PDI was performed using the same ultrasound system as for 
conventional TRUS. The power Doppler gain was set to a point below 
the  range  at  which  blood  flow in  the  neurovascular  bundles  was 
identified with no background artefact. Scanning to detect flow was 
continued  for  10 min  in  each  patient.  The  vascularization  of  a 
hypoechoic lesion in the PZ was evaluated by comparison with that of 
the area surrounding it. When a hypoechoic lesion contained more 
vessels than other PZ areas, it was defined as a hypervascular area. 
Equivocal and isoechoic lesions were defined as hypervascular area 
when these lesions were seen as abnormal vascular areas. 
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All patients underwent systematic core biopsies initially at the 
hypervascular areas and hypoechoic areas if seen and then extended 
sextant biopsy was taken from the prostate. 18 G (Bard Urological, 
Covington,  GA) automatic  core biopsy needles were used.  Biopsy 
samples  from  each  site  were  placed  in  separate  containers  of 
formalin and labelled as to the site of origin. The biopsy results were 
analysed  statistically  to  evaluate  the  differential  efficacy  of  the 
hypoechoic nodule and hypervascular areas.
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RESULTS
A total of 129 patients were included in the study period.
75 patients (58%) had cancer detected in the biopsy
Table-1: Age group of patients
Age Group Number
<55 1(0.7%)
56-60 33(25.5%)
61-65 39(30.2%)
66-70 33(25.5%)
71-75 12(9.3%)
76-80 11(8.8%)
Grand Total 129(100%)
The mean age group of the patients was 65.63 years in the age 
range  between  55  and  80  years.  The  most  common  age  group 
involved was between 56 and 70 years involving 80% of the patients. 
49 of the 129 (37%) patients had a normal DRE.
PSA value
The PSA value of the patients ranged from 3 ng / ml to 632 ng / ml 
with a mean value of 41.4 ng / ml.
Table-2:  PSA group of patients
PSA Group(ng/ml) Number
<4 1(0.7%)
4--10 14(10.8%)
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11--20 37(28.6%)
21-50 58(44.9%)
>50 19(15%)
Grand Total 129(100%)
Prostate volume
Table-3: Prostate volume of patients
Prostate volume Number
<25 g 55(42.6%)
26-50 g 62(48%)
>50 g 12(9.4%)
Grand Total 129(100%)
The mean prostate volume was 32.7g in the range between 12 and 
155g.
Relation of cancer with various parameters
Age group
The  proportion  of  patients  who  are  negative  for  cancer  are 
proportionately  more  in  the  age  group  56-60  years.  The  highest 
incidence of cancer was in the age group 66-70 years. All the patients 
in the age group above 70 years had cancer. However, the difference 
in age distribution was not statistically significant.
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Table-4: Relation of cancer with age group
Age Gp 
(Yrs) Ca present No Ca Total
<55 1 0 1
56-60 15 18 33
61-65 19 20 39
66-70 19 14 33
71-75 12 0 12
76-80 9 2 11
Grand Total 75 54 129
p-0.129
PSA level
Table-5: Relation of cancer with PSA group
PSA Gp(ng/mi) Ca present No Ca Total
<4 1 0 1
4--10 2 12 14
11--20 21 16 37
21-50 38 20 58
>50 13 6 19
Grand Total 75 54 129
p-0.02
75% of patients with PSA between 4 and 10 ng/ml were negative for 
malignancy. Even with a PSA of > 50 ng/ml had negative result for 
malignancy. Most of the patients with cancer were in the PSA range 
of 21-50ng/ml.
Prostate volume and Cancer
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Patients with cancer are equally distributed among all  the prostate 
sizes.
Table-6: Relation of prostate volume with cancer
Prostate 
vol. Ca present No Ca Total
<25 29 26 55
26-50 38 24 62
>50 8 4 12
Grand 
Total 75 54 129
p-0.66
DRE and tumour
Table-7: Relation of DRE with cancer
DRE Ca present No Ca Total
+ ve 56 24 80
- ve 19 30 49
Grand 
Total 75 54 129
p-0.004
70% of patients with positive DRE had positive biopsy.
Correlation between Hypoechoic area and carcinoma
Table-8: Relation of hypoechoic area with cancer
Hypo. area Ca present No Ca Total
Yes 47 18 65
No* 28 36 64
Grand Total 75 54 129
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*- Absent hypoechoic area / negative biopsy
The  sensitivity  of  hypoechoic  nodule  in  the  detection  of  prostate 
cancer is 62.7%, Specificity is 66.7%, Positive Predictive value 72.3% 
and Negative predictive value is 56%.
Correlation between hypervascular area and carcinoma
Table-9: Relation of hypervascular area with cancer
Hypervasculari
ty Ca present No Ca Total
Yes 66 12 78
No* 9 42 51
Grand Total 75 54 129
*- Absent hypervascular area / negative biopsy
The sensitivity,  specificity,  PPV,  NPV of  hypervascular  area in  the 
detection  of  ca  prostate  are  88.5%,  79.8%,  84.6%,  82.3% 
respectively.
Correlation between hypervascularity in hypoechoic area and 
cancer
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Table-10: Relation of hypervascularity in hypoechoic area with 
cancer
Hypervascularity 
in hypoechoic 
lesion
Ca 
present No Ca Total
Yes 34 1 35
No 41 53 94
Grand Total 75 54 129
The sensitivity, specificity, PPV, NPV of hypervascularity in the 
hypoechoic nodule in the detection of ca prostate are  45.3%, 98%, 
97%, 56.3% respectively
Statistical comparison of parameters
Table-11: Comparison of parameters
Hypervascul
ar
Area
Hypoechoic
Area
Hypervascularity 
in hypoechoic 
area
Sensitivit
y
88.5% 62.7%* 45.7%*
Specificit
y
79.8% 66.7% β 98%*
PPV 84.6% 72.3% β 97%¶
NPV 82.3% 56%.* 56.3%*
¶-p-Not significant, *-p<0.01, β-p<0.05 (compared with PDI)
Complications
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A total of 16 patients had complications. Febrile UTI was the most 
common  complication  involving  8  patients. All  were  managed 
conservatively. 
Table-12: Complications
Complication Number
UTI 8
Retention 7
Bleeding 4
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DISCUSSION
Prostate  cancer  is  the  most  common non cutaneous cancer 
involving men. Nowadays, most of the prostate cancer is diagnosed 
incidentally, at least in the western countries. In our country most of 
the patients present with symptoms such as LUTS or other metastatic 
symptoms.
As the diagnostic modalities such as serum PSA and DRE have 
significant  false  positive  and  false  negative  rates,  histological 
diagnosis by TRUS guided biopsy is considered the gold standard to 
diagnose  prostate  cancer.   Though  it  is  considered  the  primary 
investigation,  it  has only 85% sensitivity and 80% specificity,  even 
with extended core biopsy.
To increase the yield various associated modalities are used, 
such as the power Doppler imaging. In our study of 129 patients we 
evaluated the efficiency of power Doppler imaging in the detection of 
prostate cancer.
The mean age of the patients was 65.6 years ranging from 55 
to 80 years, majority were in the age group between 56 and 70 years, 
around 80%. The age group of  our population was comparable to 
those in the literature,  involving prostate cancer.  On stratifying the 
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patients  according  to  the  age  group,  patients  in  the  age  group 
between 56 and 70 years  had  proportionately  higher  incidence  of 
negative biopsies and the age group of 66 to 70 years had higher 
incidence of positive biopsies. This shows the increasing incidence of 
prostate cancer with age.
Only 10% of the patients had prostate size of more than 50ml. 
this shows that size of the prostate does not signify the presence or 
absence  of  malignancy.  The  mean  prostate  size  was  32.7  grams 
ranging from 12 to 155 ml. Prostate size did not correlate with the 
presence of ca prostate, correlation coefficient -0.06..
Serum  PSA  is  the  other  important  investigation  done  to 
diagnose prostate cancer. PSA ranged from 3 ng/ml to 756ng/ml. The 
mean PSA was 41.4 ng/ml. The mean serum PSA in cancer positive 
patients was 44.26ng/ml and 18.2 ng/ml in cancer negative patients. 
Though PSA more than 4 ng/ml is considered to be suggestive of ca 
prostate,  the  higher  incidence  of  infections  (prostatitis)  in  Indian 
patients may cause elevation of serum PSA. So a high PSA may not 
be suggestive of cancer until it is proved by biopsy. More than 70% of 
patients with PSA >20 ng/ml had carcinoma prostate.
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56 out of 75 patients with carcinoma had positive DRE. This 
gives a  sensitivity  of  76%.  This  is  considered high comparing the 
literature values of  between 40 to 70%.  This  might  be due to the 
predominant presentation of patients with higher tumour stages in the 
Indian scenario.
Hypoechoic area directed biopsy was the modality of diagnosis 
practiced  in  the  late  1980s51-52.  The  hypoechoic  nodule  directed 
biopsies  were  found  to  have  a  sensitivity  of  around  70%  and 
specificity  on  the  range  of  60%.  In  our  study,  the  sensitivity  was 
62.7%, Specificity was 66.7%, Positive Predictive value 72.3% and 
Negative predictive value was 56%.. this shows the poor efficacy of 
hypoechoic  nodule  directed  biopsy  in  the  detection  of  prostate 
cancer.
Tumours  are  found  to  be  hypervascular  due  to  the 
neovascularity.  Power Doppler imaging, which deciphers the tissue 
vascularity, may be used in the evaluation of vascularity of lesions. 
Biopsies  directed  towards  the  hypervascular  areas  were  found  to 
have a higher  sensitivity of  around 90% and specificity of  85% in 
various  studies69-81.  In  our  study,  the  sensitivity  was  88.5%  for 
detection of cancer in comparison with extende sextant  biopsy. This 
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shows that hypervascular area directed biopsy definitely scores over 
hypoechoic area directed biopsy in the detection of prostate cancer.
Overall 58% patients were detected to have cancer. It is higher 
when compared to the literature, which varies from 36% to 55%. The 
higher percentage in our study could be due to the large number of 
patients  with  both  elevated  PSA  and  positive  DRE.  The  Indian 
patients moreover present late compared with the west. The overall 
sensitivity of power Doppler in the detection of prostate cancer in our 
study was 88.5 % similar to the previous studies. The specificity of 
79.8%  was  comparable  with  the  world  literature.  The  positive 
predictive value of 84.6% was similar to other studies. The negative 
predictive  value  of  82.3%  was  comparably  less  than  the  world 
literature which varies from 78 to 94%.
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Table-13: Comparison of studies with power doppler
Ca (%)
No.
(Pts)
Sen Spe PPV NPV Study
36 136 82.8%, 78.8%, 87.9% 89.7%, Remzi73
40 108 90%, 90% 84%, 94% Satoru74
55 323 92.4% 72% 83% 80.6% Sauvain78
36 36 90%, 75% 82% 88% Sakarya80
42 28 74%, 96% 74% 78% Franco83
40 108 90% 90% 84% 94%
Takahashi6
9
58 129 88.5% 79.8% 84.6% 82.3% *
* - present study
One important point to note in our study is that in 3 patients with 
carcinoma, the tumour was picked up by hypervascular area directed 
biopsy,  but  it  was  not  diagnosed  by  10  core  biopsy.  In  all  these 
patients the prostate volume was more than 50ml. Though the values 
are  not  statistically  significant,  we  can  advise  hypervascular  area 
directed biopsy combined with standard 10 core biopsy in patients 
with large prostates. This finding correlates with the study by Saturo 
et al where 3 patients with a negative sextant biopsy had a positive 
targeted biopsy.75.
The  presence  of  hypervascularity  in  hypoechoic  nodules  is 
associated with a positive predictive value of 98%. So if a patient has 
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a hypoechoic nodule showing hypervascularity, this is most likely to 
have a focus of tumour.
On  evaluating  the  statistical  parameters  using  the  test  of 
proportions, the difference in sensitivity and NPV between PDI and 
grey scale imaging was statistically significant with p value of <0.01. 
Difference in specificity and PPV had a p value of < 0.05.
The complication rate in our study was 10%. This is equal to 
those reported in literature. The most common complication was UTI, 
which was managed conservatively with antibiotics. These infections 
do occur  even after  antibiotic  prophylaxis,  so  patients  need to  be 
counselled  prior  to  procedure.  4  patients  had  minimal  hematuria 
which was managed conservatively.
To conclude, transrectal ultrasound with power Doppler imaging 
guided biopsy is more sensitive and specific compared to grey scale 
imaging. Extended core biopsy protocol though, still remains the gold 
standard. We would like to recommend hypervascular area directed 
biopsies  combined  with  standard  extended  core  biopsies  in  large 
prostates to increase the yield.
71
CONCLUSION
To  conclude,  transrectal  ultrasound  with  power  Doppler  imaging 
guided biopsy is more sensitive and specific compared to grey scale 
imaging. Extended core biopsy protocol though, still remains the gold 
standard. We would like to recommend hypervascular area directed 
biopsies combined with standard extended core biopsies to increase 
the yield.
Power Doppler  imaging guided hypervascular  area directed biopsy 
gives a better diagnostic yield there by reducing the number of repeat 
biopsies.
Power Doppler imaging guided hypervascular area directed biopsy is 
efficient  in  the  detection  of  prostate  cancer  in  comparison  with 
hypoechoic nodule directed biopsy.
SUGGESTIONS:
Power Doppler guided targeted biopsy of hypervascular area, may be 
combined with extended core biopsy to increase the yield  of  core 
biopsy.
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ABBREVATIONS
PSA  - Prostate Specific Antigen
DRE - Digital Rectal Examination
TRUS  -Trans Rectal Ultra Sonography
BPH - Benign Prostatic Hyperplasia
MRI – Magnetic Resonance Imaging
IES – Invaginated Extra prostatic Space
PZ – Peripheral Zone
TZ – Trasitional Zone
SV – Seminal Vesicle
CE – TRUS – Contrast Enhanced Trans Rectal Ultra Sonography
PDUS – Power Doppler Ultrasonography
LUTS – Lower Urinary Tract Infection
PDI – Power Doppler Imaging
MVD – Micro Vessel Density
HVL – Hyper Vascular Lesion
PPV – Positive Predictive Value
NPV – Negative Predictive Value
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